Ftse Mib
38.699,89
-0,21%
DAX
23.080,52
-1,57%
S&P 500
5.738,52
-1,78%
NASDAQ
18.069,26
-2,61%
Bitcoin
88.958,69
-1,08%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cogent Biosciences Inc (COGT) Cogent Biosciences Inc (COGT) Notizie

Cogent Biosciences Inc

COGT
7,41
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
27/2/202514:00GLOBECogent Biosciences Announces SUMMIT Continues to Showcase..
25/2/202522:02EDGAR2Form S-8 - Securities to be offered to employees in employee..
25/2/202514:20EDGAR2Form 8-K - Current report
25/2/202514:00GLOBECogent Biosciences Reports Recent Business Highlights and..
12/2/202522:35EDGAR2Form SCHEDULE 13G - Statement of Beneficial Ownership by..
10/2/202515:15GLOBECogent Biosciences Announces Bezuclastinib Poster in..
30/1/202514:00GLOBECogent Biosciences to Participate in the Guggenheim Biotech..
27/1/202523:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/1/202523:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/1/202522:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/1/202522:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/1/202522:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/1/202513:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/1/202514:00GLOBECogent Biosciences Announces Planned 2025 Milestones for..
08/1/202514:00GLOBECogent Biosciences Announces Presentation at the 43rd..
09/12/202422:01EDGAR2Form 8-K - Current report
09/12/202413:00GLOBECogent Biosciences Announces Updated Clinical Results from..
08/12/202418:00GLOBECogent Biosciences Announces Positive Updated Data from..
14/11/202422:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202418:24EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202414:00GLOBECogent Biosciences Reports Recent Business Highlights..
05/11/202415:00GLOBECogent Biosciences Announces Bezuclastinib Presentations at..
23/10/202413:00GLOBECogent Biosciences Announces Pipeline Expansion into KRAS..
03/9/202414:15EDGAR2Form 8-K - Current report
03/9/202414:00GLOBECogent Biosciences Announces Phase 3 PEAK Trial in Patients..
06/8/202422:53EDGAR2Form S-8 - Securities to be offered to employees in employee..
06/8/202414:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/8/202414:20EDGAR2Form 8-K - Current report
06/8/202414:00GLOBECogent Biosciences Reports Recent Business Highlights and..
27/6/202414:00GLOBECogent Biosciences Announces Positive FDA Meeting and..
14/6/202413:30GLOBECogent Biosciences Announces Additional Clinical Data from..
14/6/202401:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202401:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202401:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202401:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202412:06EDGAR2Form SC 13D/A - General statement of acquisition of..
13/6/202403:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202422:02EDGAR2Form 8-K - Current report
29/5/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202422:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
23/5/202423:05GLOBECogent Biosciences Appoints Cole Pinnow as Chief Commercial..
23/5/202423:01GLOBECogent Biosciences Announces Positive Updated Lead-In Data..
07/5/202414:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202414:19EDGAR2Form 8-K - Current report
07/5/202414:00GLOBECogent Biosciences Reports First Quarter 2024 Financial..
09/4/202415:00GLOBECogent Biosciences Presents Data Highlighting Potential..
Apertura: Min: Max:
Chiusura: 7,41

La tua Cronologia

NASDAQ
COGT
Cogent Biosciences
LSE
96PZ
Res.mort.10'b's
BIT
I10480
IT0005616245 20250602 7.25
NASDAQ
ABNZBXX
Torontodominion Bank Aut...
LSE
70NU
4q%07dec2027p
BIT
ECRP
Amundi Index Barclays Eu...
AMEX
PBUS
Invesco MSCI USA ETF
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci